Discordance with local guidelines for adjuvant chemotherapy in breast cancer: reasons and effect on survival.

Date publication

mars 2011

Journal

Clinical breast cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr COUTANT Charles

Tous les auteurs :
Chéreau E, Coutant C, Gligorov J, Lesieur B, Antoine M, Daraï E, Uzan S, Rouzier R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/21421522

Résumé

Adjuvant treatments are usually decided according to guidelines. However, many individual factors, such as performance status, patient refusal, complex interactions between factors (eg, discrepancies between grade and Ki 67), and complex clinical features (borderline age or tumor size) may introduce discrepancies. The aim of this study was to quantify discrepancies between local guidelines and patient management.

Mots clés

Adult, Aged, Aged, 80 and over, Antineoplastic Agents, therapeutic use, Breast Neoplasms, drug therapy, Carcinoma, Ductal, Breast, drug therapy, Carcinoma, Intraductal, Noninfiltrating, drug therapy, Carcinoma, Lobular, drug therapy, Chemotherapy, Adjuvant, Female, Humans, Middle Aged, Practice Guidelines as Topic, Receptor, ErbB-2, metabolism, Receptors, Estrogen, metabolism, Receptors, Progesterone, metabolism, Survival Rate, Treatment Outcome, Young Adult

Référence

Clin. Breast Cancer. 2011 Mar;11(1):46-51